U.S. drug distributor Cencora raised its annual profit forecast on Wednesday, driven by robust demand for costly specialty medicines and weight-loss drugs.

Cencora gets a buy rating, agreeing with today's consensus from Wall St. The sector and macro environment point to continued demand for the healthcare supplies and niche specialty drugs Cencora ...

Shareholders might have noticed that Cencora, Inc. (NYSE:COR) filed its quarterly result this time last week. The early response was not positive, with shares down 3.1% to US$283 in the past week.

Shares of Cencora (COR) have been strong performers lately, with the stock up 11.2% over the past month. The stock hit a new 52-week high of $309.35 in the previous session. Cencora has gained 35. ...

Shares of Cencora Inc. COR shed 1.95% to $281.16 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.36% to 5,158.20 and Dow ...

CONSHOHOCKEN, Pa. (AP) — CONSHOHOCKEN, Pa. (AP) — Cencora, Inc. (COR) on Wednesday reported fiscal second-quarter profit of $717.9 million. On a per-share basis, the Conshohocken, Pennsylvania ...

Conshohocken, Pennsylvania-based Cencora, Inc. (COR) is a pharmaceutical sourcing and distribution company. With a market cap of approximately $54 billion, Cencora operates through the U.S ...